Evidence map›Paper›PMID 36646807›Full record

ArticleBritish journal of cancer2023

Norepinephrine inhibits CD8

Qishun Geng, Lifeng Li, Zhibo Shen, Yuanyuan Zheng, Longhao Wang, Ruyue Xue, Wenhua Xue, Mengle Peng, Jie Zhao

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer.Cancer drug resistance (Alhambra, Calif.) · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Qishun Geng *Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Lifeng Li *Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Zhibo Shen *Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Yuanyuan ZhengInternet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Longhao WangInternet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Ruyue XueInternet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Wenhua XueInternet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Mengle PengInternet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Jie ZhaoInternet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China. zhaojie@zzu.edu.cn.ORCID 0000-0003-1168-8384
First Affiliated Hospital of Zhengzhou University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMental stress-induced neurotransmitters can affect the immune system in various ways. Therefore, a better understanding of the role of neurotransmitters in the tumour immune microenvironment is expected to promote the development of novel anti-tumour therapies.

methodsIn this study, we analysed the plasma levels of neurotransmitters in anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb)-resistance patients and sensitive patients, to identify significantly different neurotransmitters. Subsequently, animal experiments and experiments in vitro were used to reveal the specific mechanism of norepinephrine's (NE) effect on immunotherapy.

resultsThe plasma NE levels were higher in anti-PD-1 mAb-resistance patients, which may be the main cause of anti-PD-1 mAb resistance. Then, from the perspective of the immunosuppressive microenvironment to explore the specific mechanism of NE-induced anti-PD-1 mAb resistance, we found that NE can affect the secretion of C-X-C Motif Chemokine Ligand 9 (CXCL9) and adenosine (ADO) in tumour cells, thereby inhibiting chemotaxis and function of CD8

conclusionNE can affect the secretion of CXCL9 and ADO in tumour cells, thereby inhibiting chemotaxis and the function of CD8

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsAntibodies, MonoclonalCD8-Positive T-LymphocytesCell Line, TumorNorepinephrineTumor MicroenvironmentAntibodies, MonoclonalNorepinephrine

Identifiers

PMID36646807
PMCPMC10050078
OpenAlexW4316467944

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read28
table measurements read4
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.